EUVIMEDEUVIMED entdecken
Open Access

A Genomic Analysis of Usher Syndrome: Population‐Scale Prevalence and Therapeutic Targets

Shelby E Redfield iD, Stephanie A Mauriac iD, Gwenaëlle S Géléoc iD, A Eliot Shearer iD

American Journal of Medical Genetics Part C: Seminars in Medical Genetics · 2025-09 · 199 (3) · 218-227

DOI: 10.1002/ajmg.c.32142 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Medical Genetics Part C: Seminars in Medical Genetics, online erschienen am 18.04.2025. Verfasst von Shelby E Redfield und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology and Communication Enhancement, Boston Children's Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Usher Syndromes, Genomics. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Boston Children's Translational Research Program, Manton Center for Orphan Disease Research, Boston Children's Hospital, NIDCD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Usher syndrome, the most common form of deaf‐blindness, displays extensive genetic, allelic, and phenotypic heterogeneity. The dual sensory impairment associated with this autosomal recessive disorder makes Usher syndrome an important target for gene therapy, with dozens of published preclinical studies targeting multiple Usher syndrome genes and using multiple gene therapy strategies. Nine genes have been conclusively linked to Usher syndrome; however, data on the prevalence and contribution of specific genetic variants is lacking. Such information is essential to choosing a favorable target gene or therapeutic approach during clinical trial design. Here, we used large genomic databases to systematically evaluate the genomics of Usher syndrome. We ascertained pathogenic Usher syndrome variants from three clinical databases and determined the occurrence of these pathogenic Usher syndrome variants within: (1) a publicly available dataset including worldwide populations (GnomAD), (2) a cohort of 3888 children without hearing loss, and (3) 637 children with hearing loss. Results show significant variability in the frequency of Usher syndrome variants by gene and genetic ancestry. 1% of control subjects carry a pathogenic USH variant. Pathogenic variants in USH2A are the most prevalent, at 1 in 150 individuals (0.0062). Calculated general population prevalence for all Usher syndrome subtypes is 1 in ~29,000, indicating that 30,405 individuals in the United States and 721,769 individuals worldwide are affected. We estimate that 324 babies in the United States and 12,090 worldwide are born with Usher syndrome each year. We identify key targets for genetic therapy based on population‐level prevalence including a focus on alternatives to gene replacement therapies, specifically for USH2A .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Usher SyndromesGenomicsHumansPrevalenceExtracellular Matrix ProteinsChildGenetic TherapyDatabases, GeneticMutation

Stichwörter der Autor:innen

deafnessdeaf‐blindnesshearing lossretinitis pigmentosa

Substanzen

USH2A protein, humanExtracellular Matrix Proteins

Autor:innen und Institutionen

  • Department of Otolaryngology and Communication Enhancement, Boston Children's Hospital, Boston, Massachusetts, USA.
  • Children's Rare Disease Collaborative, Department of Information Technology, Boston Children's Hospital, Boston, Massachusetts, USA.

ORCID-Profile: Shelby E Redfield, Stephanie A Mauriac, Gwenaëlle S Géléoc, A Eliot Shearer

Förderung

  • Boston Children's Translational Research Program
  • Manton Center for Orphan Disease Research, Boston Children's Hospital
  • NIDCD NIH HHS
  • Rosamund Stone Zander Translational Neuroscience Center
  • Barber Gene Therapy Research Fund
  • Usher Syndrome Society
  • Boston Children's Rare Disease Cohort Initiative
  • National Institute on Deafness and Other Communication Disorders

Zitieren

APA

Redfield, S. E., Mauriac, S. A., Géléoc, G. S., & Shearer, A. E. (2025). A Genomic Analysis of Usher Syndrome: Population‐Scale Prevalence and Therapeutic Targets. American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 199(3), 218-227. https://doi.org/10.1002/ajmg.c.32142

Vancouver

Redfield SE, Mauriac SA, Géléoc GS, Shearer AE. A Genomic Analysis of Usher Syndrome: Population‐Scale Prevalence and Therapeutic Targets. American Journal of Medical Genetics Part C: Seminars in Medical Genetics. 2025;199(3):218-227. doi:10.1002/ajmg.c.32142

BibTeX
@article{Redfield2025,
  author = {Redfield, Shelby E and Mauriac, Stephanie A and Géléoc, Gwenaëlle S and Shearer, A Eliot},
  title = {A Genomic Analysis of Usher Syndrome: Population‐Scale Prevalence and Therapeutic Targets},
  journal = {American Journal of Medical Genetics Part C: Seminars in Medical Genetics},
  year = {2025},
  volume = {199},
  number = {3},
  pages = {218--227},
  doi = {10.1002/ajmg.c.32142}
}
Kostenlos starten →